Could This Little-Known Company's Vaccine Candidate Leapfrog Moderna and Pfizer?
Investors looking for exposure to the COVID-19 vaccine market may naturally lean toward Moderna (NASDAQ: MRNA), which developed mRNA-1273, and Pfizer (NYSE: PFE), which developed BNT162b2 in collaboration with BioNTech. These companies were the first to earn Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for their respective products.
And while millions of people continue to receive doses of mRNA-1273 and BNT162b2, Novavax has yet to earn an EUA for its candidate, while Johnson & Johnson's vaccination efforts were paused in the U.S. because six patients experienced blood clots after receiving the pharma giant's vaccine. These factors arguably make Moderna and Pfizer the leaders in the coronavirus vaccine market, at least in the U.S.
But there is a small-cap company looking to make waves in this space: Ocugen (NASDAQ: OCGN), a biotech headquartered in Pennsylvania. Ocugen's stock has soared by 208.7% year to date as investors cheered its potential entry into the COVID-19 vaccine market. But is this biotech a better bet than Moderna and Pfizer?
Source Fool.com
